The BeLimumab Antiphospholipid Syndrome Trial (BLAST)

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2022

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias

AIM:

The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent aPL positivity and clinical features attributable to aPL that are resistant to warfarin and/or heparin.
Epistemonikos ID: dd34b6a1b9c493cd94e1e1ce03492aa1a9100917
First added on: May 09, 2024